Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: Report of an efficacy study

Table 1 Relationship between the patients’ profiles and their outcomes from Helicobacter pylori eradication

	Successful eradication	Yes	No	Total number of subjects
Age of the patient vs eradication outcome
Age grouping of patient	0-39 yr	19	3	22
	40-59 yr	14	1	15
	≥ 60 yr	8	2	10
	Total	41 (mean age 41 ± 17)	6 (mean age 48 ± 16)
	P value 0.611 (χ2 = 0.986)
Gender vs outcome of eradication therapy
Gender	Male	16	2	18
	Female	25	4	29
	Total	41	6	47
	P value 0.582 (χ2 = 0.072)
Patients’ clinical presentation vs outcomes of eradication treatment
Clinical presentation	Dyspepsia	34	3	37
	GERD	2	2	4
	GI bleeding	2	0	2
	Multiple presentation	3	1	4
	Total	41	6	47
	P value 0.088 9 (χ2 = 6.531)

GI: Gastrointestinal; GERD: Gastroesophageal reflux disease.

Table 2 Demographics, clinical features and response patterns of the subjects to the Helicobacter pylori eradication regimes n (%)

Factor	Seven-day arm	Ten-day arm	P value
Age range (mean ± SD)	13-71 (41.56 ± 16.94)	18-80 (44.93 ± 16.94)	0.504
Sex			0.581
Male	6 (33.3)	12 (41.4)
Female	12 (66.7)	17 (58.6)
Symptomatic improvement			0.215
Yes	17 (94.4)	29 (100.0)
No	1 (5.6)	0 (0.0)
Successful eradication			0.789
Yes	16 (88.9)	25 (86.2)
No	2 (11.1)	4 (13.8)